Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

As market values increase for computational biology and data science, biopharma companies are looking to hire R&D ...

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

Job postings in California took a dip in December during the holiday period, but activity is expected to pick up in January.

High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk ...

In this episode of Denatured, BioSpace's Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the ...

Gary Stibel is the founder, CEO, and managing partner of the New England Consulting Group. With over half a century of experience, Gary has worked in nearly every segment of the healthcare and life ...